Letters, Testimony & Comments

January 28, 2008
Re: CMS-1392-FC (Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates) Dear Administrator Weems: The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on...
January 22, 2008
ACCESS AND BENEFIT-SHARING: PEER REVIEW PROCESS FOR ABS STUDIES COMMENTS OF THE BIOTECHNOLOGY INDUSTRY ORGANIZATION The Biotechnology Industry Organization (BIO) would like to express its appreciation to the Secretariat for making the...
January 10, 2008
Re: CMS–10224 (Agency Information Collection Activities: Proposed Collection; Comment Request; HCPCS Level II Code Modification Request Process) Dear Ms. Lovett: The Biotechnology Industry Organization (BIO) appreciates this opportunity...
January 1, 2008
BIO commends the IGWG for its work on a global strategy and plan of action that, according to its mandate, will aim at "securing an enhanced and sustainable basis for needs-driven, essential health R&D relevant to diseases that...
December 21, 2007
Re: CMS-2238-P (Medicaid Program; Prescription Drugs) Dear Acting Administrator Weems: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid Services’ (CMS) Final...
December 10, 2007
BIO's comments on proposed changes to the 2010 HCPCS Level II Modification Process
December 6, 2007
Re: Comments on the USP Draft Medicare Model Guidelines Dear Dr. Perfetto: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the United States Pharmacopeia’s (USP) Draft Medicare Model Guidelines...
November 30, 2007
Letter from BIO suggesting agenda items for discussions at the next (6th) meeting of the working group on Access and Benefit Sharing in Geneva.
November 7, 2007
BIO's comments to AHRQ regarding the Guide to Conducting Comparative Effectiveness Reviews
November 5, 2007
The Biotechnology Industry Organization Presents a Luncheon Seminar: From Biotechnology Innovation to Global Health Solutions: Solutions for Diseases Affecting Developing Countries Wednesday, 07 November 2007 13h00 to 15h00 Pavilion of...
October 30, 2007
The Comments of the Biotechnology Industry Organization on the United States Patent & Trademark Office Proposed Rule Changes Concerning Biological Deposits April 21, 2008 Comments to Proposed Rulemaking Entitled: Revision to the Time for...
October 27, 2007
BIO addresses concerns to FASB’s Staff Position on accounting for instrument C and conventional convertible debt.